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ABSTRACT
Adenoviruses (ADV) are emerging as important causes of morbidity and mortality in patients undergoing
hematopoietic stem cell transplantation (HSCT). In mainly non-T–cell depleted HSCT recipients, we ana-
lyzed the incidence of ADV infection, risk factors for infection, the effect of ganciclovir administered for
prevention of cytomegalovirus (CMV), and the impact of ADV infection on survival. The overall incidence of
ADV, irrespective of the method of detection, was 8.5% (450/5233) and 12.3% (43/348) after the first or second
allogeneic HSCT, and 6.3% (78/1219) and 6.5% (5/77) after the first or second autologous HSCT, respectively.
The most frequent sites of infection and disease were stool and gastrointestinal tract, respectively. Statistically
significant risk factors associated with ADV infections among allogeneic recipients included younger age, grade
II to IV graft-versus-host disease, year of transplantation, and a second allogeneic HSCT. Furthermore,
allogeneic patients seronegative for CMV at transplantation and seropositive allogeneic patients who did not
receive ganciclovir, either at engraftment or as pre-emptive therapy on CMV reactivation, were at higher risk
of developing ADV infections compared with seropositive patients who received ganciclovir (odds ratio1.8,
95% confidence interval (CI) 1.2 to 2.8, P.005 and odds ratio3.4, 95% CI 2.1 to 5.55, P<.0001, respectively).
The hazard of overall mortality was higher in patients who contracted ADV compared with those who did not
(hazard ratio 1.5, 95% CI 1.3 to 1.7, P<.0001). This study shows that ADV infections are associated with poor
transplantation outcome in T-cell repleted HSCT recipients. Ganciclovir, given for CMV prevention, may
have a protective effect. Controlled treatment and prevention studies are warranted.
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INTRODUCTION
Adenovirus (ADV) infections are emerging as life-
threatening complications in immunocompromised
hosts [1]. In hematopoietic stem cell transplantation
(HSCT), ADV cause organ-speciﬁc syndromes such
as hemorrhagic cystitis [2-4], nephritis [5,6], enteritis
[7], hepatitis [8], pneumonia [9], encephalitis [10], and
multiorgan failure [9,11]. Previous studies in T-cell
depleted HSCT recipients, including those after hap-
loidentical transplantation, report that ADV infec-
tions have a signiﬁcant impact on morbidity and mor-
tality post-HSCT [12-17]. However, there is limited
information on the recent epidemiology of ADV in
non-T–cell depleted HSCT recipients. Moreover, lit-
tle is known about the impact of the recent widespread
use of ganciclovir for prevention of cytomegalovirus
(CMV) on the occurrence of ADV. This of interest
because of the in vitro activity of ganciclovir against
ADV [18-32]. The goal of our study was to estimate
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the incidence of ADV infections and ADV disease in a
large cohort of mainly non-T–cell depleted HSCT
recipients, to identify risk factors associated with
ADV, to examine the impact of ganciclovir for pre-
vention of CMV infection on the occurrence of ADV,
and to assess the impact of ADV on survival.
METHODS
Study Population
The study population consisted of 5233 allogeneic
and 1219 autologous transplantations performed at
the Fred Hutchinson Cancer Research Center (Seat-
tle, WA) between January 1, 1978 and December 31,
1998. Of the transplantations studied, 6.6% (348/
5233) were second allogeneic and 3.5% (43/1219)
were second autologous transplantations. Clinical and
laboratory data, and autopsy and histology reports
were extracted from the computerized database and
charts. Graft-versus-host disease (GVHD) was graded
according to established criteria [33]. T-cell depletion
and CD34 selection were performed as previously
described [34-36]. The study was approved by the
Institutional Review Board at Fred Hutchinson Can-
cer Research Center.
Infection Control Guidelines
Infection control measures changed throughout
the study period. A strict hand washing policy was in
place throughout the study period. Laminar airﬂow
rooms were used until 1992. Surgical masks were used
until 1993, when a general mask policy was discontin-
ued. Subsequently, masks were only used at the time
of room entry of patients with upper respiratory
symptoms. Starting in 1997, all health care workers
and visitors with uncontrolled respiratory secretions
were restricted from access to patients. Patients with
upper respiratory symptoms underwent virologic test-
ing of nasopharyngeal swab and/or wash specimens
and were placed in isolation until both asymptomatic
and negative by culture and direct ﬂuorescent anti-
body testing for respiratory viruses.
Definitions
Adenovirus infection was deﬁned as detection of
ADV in ﬂuid or tissue specimens by conventional or
centrifugation (shell vial) culture, direct ﬂuorescent
antibody, or enzyme immunoassay (EIA). Adenovirus
disease was deﬁned as tissue from biopsy and/or au-
topsy and/or bronchoalveolar lavage positive for ADV
by routine histology, with or without immunocyto-
chemistry, or culture. Organ dysfunction was not re-
quired to deﬁne disease. Disease was considered dis-
seminated if 2 or more organ systems were involved.
Laboratory Evaluation
From the beginning of the study period through
July, 31 1994, weekly surveillance conventional cul-
tures of throat, urine, and stool were obtained from
most inpatients and every 2 weeks from most outpa-
tients from the day of transplantation (deﬁned as day
0) until the earliest of last routine follow-up before
discharge home or death. Other sites were cultured as
clinically indicated. Other techniques for clinical ADV
identiﬁcation included shell vial cultures from August
1988 onwards, direct ﬂuorescent antibody and EIA on
stool samples from August 1988 onwards. To reduce
cost, conventional culture was applied on ﬂuid sam-
ples only as clinically indicated from all sites from
August 1994 onwards. Biopsy and autopsy specimen
were routinely processed for histologic studies to de-
tect the adenoviral characteristic cytopathic changes
by routine histology, immunocytochemistry, or cul-
ture throughout the study [37].
Risk Factor Analysis
To identify risk factors associated with the hazard
of development of ADV infections, the following vari-
ables were evaluated: age at transplantation, year of
transplantation, ﬁrst and second transplantation, sea-
son of transplantation, patient gender, type of donor,
conditioning regimens (total body irradiation-con-
taining regimens versus non-total body irradiation-
containing regimens), CMV serology at transplanta-
tion, administration of ganciclovir, and diagnosis of
underlying disease. Diseases were further categorized
as low, intermediate, and high risk. The low-risk
group was composed of patients with chronic myelog-
enous leukemia in chronic phase. The high-risk group
was composed of patients who underwent transplan-
tation in relapse and chronic myelogenous leukemia
patients in blast crisis. All other patients were catego-
rized in the intermediate-risk group. For patients un-
dergoing allogeneic HSCT, other variables included
in the analysis were patient/donor gender, patient/
donor CMV status at transplantation, development of
overall acute GVHD, and skin, gut, and liver GVHD.
Renal and liver functions were evaluated based on
serum creatinine and bilirubin levels, respectively,
which were considered as continuous variables
throughout the study period.
Administration of Ganciclovir, Incidence of
Cytomegalovirus, and Occurrence of Adenovirus
Infections
To evaluate the correlation of ganciclovir admin-
istration and occurrence of ADV infections, we used
the guidelines for the use of ganciclovir that were
based on CMV serology status and CMV pp65 anti-
genemia. If the start date of ganciclovir therapy was
after the documentation of ADV infection, ganciclovir
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was assumed to have not been given for purposes of
analysis. Guidelines were as follows: before July 1990,
no patients received prophylactic ganciclovir; from
August 1990 through August 1991, seropositive pa-
tients at transplantation were randomized to receive
either ganciclovir or placebo at engraftment, deﬁned
as absolute neutrophil count (ANC)  750/L [38].
Patients off protocol did not receive ganciclovir. From
September 1991 through March 1992, all CMV sero-
positive patients at transplantation received ganciclo-
vir when ANC exceeded 750/L; from April 1992
through March 1994, patients were randomized either
to receive ganciclovir (ganciclovir arm of the protocol)
or to receive ganciclovir for CMV antigenemia level
of 2 positive cells or greater (placebo arm of the
protocol), patients off protocol received ganciclovir
when ANC exceeded 750/L; after April 1994, pa-
tients undergoing allogeneic HSCT received ganci-
clovir for CMV antigenemia as described [39,40]; pa-
tients undergoing autologous HSCT received
ganciclovir for antigenemia  5 positive cells per
slide. Finally, incidence of CMV infection and disease
were also correlated with incidence of ADV infection
and disease.
Statistical Methods
The occurrence of ADV infections was assessed
from the time of transplantation to time of discharge
(usually around day 60 and day 100 for most au-
tologous and allogeneic transplantations, respective-
ly), second transplantation, date of death, or occur-
rence of ADV infection, whichever occurred ﬁrst.
This time period deﬁned the number of days at risk
for each patient and each regression model for ADV
was adjusted for this number. For descriptive purposes
only, detection by any method was considered. Formal
statistical analyses were restricted to transplantations
performed between August 1988 and August 1994, a
time during which methods of detection were uniform
throughout the period. During this time, culture was
performed routinely on nonstool samples and EIA on
stool samples.
The statistical analyses associated with this time
window included 2010 consecutive allogeneic HSCT
and 530 autologous HSCT. Generalized estimating
equations were used to assess the association of vari-
ous explanatory variables with the probability of ADV
detection [41]. A logistic link function with an inde-
pendent working correlation matrix was used in the
generalized estimating equation models, where clus-
tering was performed on patients because approxi-
mately 5% of patients contributed 2 transplantations
to the data set. Odds ratios (OR) were estimated from
exponentiating the parameter estimates derived from
the generalized estimating equations regression mod-
els, and the standard errors from these models led to
conﬁdence interval estimates. The standard errors
took into account the correlation from multiple trans-
plantations from the same patient. The association of
ADV with survival was assessed by treating infection
as a time-dependent covariate. All P values resulting
from regression models were derived from the Wald
test, and no adjustments were made for multiple com-
parisons.
RESULTS
Incidence of Adenovirus after Allogeneic Stem
Cell Transplantation
Throughout the entire study period and irrespec-
tive of the method of detection, the incidence of ADV
infections and disease after the ﬁrst or second alloge-
neic transplantation was 8.5% (450/5233) and 12.3%
(43/348), respectively. T-cell depleted transplanta-
tions accounted for only 3% of both ﬁrst and second
transplantations (160/5233 and 10/348, respectively).
The incidence of ADV infection following ﬁrst or
second T-cell depleted allografting was 6% (10/160)
and 50% (5/10), respectively. Characteristics of pa-
tients developing ADV are reported in Table 1. Me-
dian time of detection of ADV was 45 days post ﬁrst
transplantation and 33 days post second transplanta-
tion. Patient distributions by age and by posttrans-
plantation day of detection are reported in Table 1.
After the ﬁrst and the second transplantation, ADV
were isolated from a single site in 88% (394/450) and
79% (34/43) of cases, respectively, and from multiple
sites in 12% (56/450) and 21% (9/43), respectively.
Sites of isolation are reported in Table 2. After the
ﬁrst transplantation, ADV were most frequently iso-
lated from feces at a median of day 40 posttransplan-
tation; the second and third most frequent sites of
isolation were urine and nose/pharynx/throat at a me-
dian of day 69 and 45 posttransplantation, respec-
tively. After the second HSCT, the most frequent site
of isolation remained feces, followed by urine.
Adenovirus Disease after Allogeneic Stem Cell
Transplantation
Among the 450 patients who developed ADV after
the ﬁrst transplantation, 23% (105/450) had a tissue
biopsy posttransplantation and/or an autopsy. Forty-
one percent (42/105) met the criteria of ADV disease,
while 61% (63/105) did not show evidence of disease.
Overall incidence of ADV disease was 9.3% (42/450)
(Table 2) and 10% (1/10) in patients who developed
ADV infection after the ﬁrst T-cell depleted trans-
plantation. Seventy-six percent (32/42) of patients had
a single organ system involved and 24% (10/42) had
disseminated disease. Overall, after the ﬁrst and the
second transplantation, 3% (15/450) and 7% (3/43) of
patients, respectively, were diagnosed with disease
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that was not preceded by documented infection by any
surveillance culture. Adenovirus disease was most fre-
quently diagnosed in the gastrointestinal (GI) tract:
overall 45% (19/42) had GI involvement and 35%
(15/42) had only GI disease. Interestingly, of the 19
patients who had GI disease, only 15% (3/19) had a
positive surveillance stool culture. Moreover, of the 7
patients with GI disease diagnosed after the introduc-
Table 1. Characteristics of Patients Developing Adenovirus Infections after Allogeneic Hematopoietic Stem Cell Transplantation
After First Transplant (%) After Second Transplant (%)
No. of patients 450 (8.5) 43 (12)
Median age at transplant (yrs) 28 (range,0.5–61) 18 (range,2–61)
Patient distribution by age (yrs)
0–20 177 (39) 22 (51)
21–30 76 (17) 9 (20)
31–40 93 (21) 6 (14)
41–50 73 (16) 4 (9)
51–60 31 (7) 1 (2)
>61 — 1
Type of donor
Matched sibling 224 (49) 27 (63)
Mismatched related 106 (24) 10 (23)
Unrelated 120 (27) 6 (14)
Source of stem cells
Bone marrow 426 (95) 30 (69)
Peripheral blood 9 (2) 8 (19)
Bone marrow and peripheral 1 (<1)
Cord blood 4 (<1)
T-cell depleted bone marrow 7 (1.5) 5 (12)
T-cell depleted peripheral 3 (<1)
Diagnosis
Hematologic malignancies
ALL 100 (23) 6 (14)
AML 106 (23) 18 (42)
CML 120 (27) 6 (14)
HD 6 (<1) 2 (5)
MDS 40 (9) 5 (11)
MM 12 (3) —
NHL 22 (5) 2 (5)
Breast cancer — —
Other solid tumor 19 (4) —
Aplastic anemia 24 (5) 3 (7)
PNH 1 (<1) 1 (<1)
Conditioning regimen
TBI >12 cGy 221 (48) 9 (20)
TBI <12 cGy 98 (21) 2 (5)
BuCy 71 (15) —
BuCy TBI 14 (3) —
Other 46 (12) 32 (75)
GVHD prophylaxis
CSP  MTX 197 (44) 9 (21)
Other 253 (56) 34 (79)
Acute GVHD
Grade 0–I 99 (22) 12 (28)
Grade II–IV 335 (74) 27 (63)
Not graded 16 (4) 4 (9)
Median day of detection of ADV 45 33
Distribution by day of detection of:
0–20 99 (22) 12 (28)
21–40 104 (23) 13 (30)
41–60 85 (19) 10 (23)
61–80 79 (18) 3 (7)
81–100 45 (10) 2 (4)
>101 38 (8) 3 (7)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HD, Hodgkin disease;
MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria;
GVHD, graft-versus-host disease; CSP, cyclosporine; MTX, methotrexate; TBI, total body irradiation; BU, busulfan; Cy, cyclophosphamide.
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tion of EIA on stool samples, only 1 had ADV de-
tected by EIA. Overall, after the second transplanta-
tion, the incidence of disease was 16% (7/43), and
42% (3/7) had disseminated disease. One patient
(20%; 1/5) was diagnosed with disease after the second
T-cell depleted transplantation. The GI tract was in-
volved in 42% (3/7) and lungs in 42% (3/7). The
overall incidence of ADV disease by year of transplan-
tation is illustrated in Figure 1.
Correlation between Occurrence of Adenovirus
and Season
Episodes of ADV infections occurred year-round
and no seasonal outbreaks were observed. During the
time window of the statistical analysis, the number of
days that each patient with ADV infection was under
observation was calculated for each season, and the
numbers for each season were similar (winter 22.5
days; spring 24.4 days; summer 24.0 days; fall 23.8
days).
Risk Factor Analysis
Univariate models for the development of ADV
infections are presented in Table 3. By multivariable
analysis, age at transplantation, year at transplanta-
Figure 1. Incidence of ADV disease by year of transplant in hema-
topoietic stem cell transplantation.
Table 2. Adenovirus Isolation from Allogeneic and Autologous Patients
Allogeneic Patients* Autologous Patients*
After First
Transplant
After Second
Transplant
After First
Transplant
After Second
Transplant
Total no. of patients 450 43 78 5
Single site of isolation 394 (88%) 34 (79%) 73 (94%) 4 (80%)
Multiple site of isolation 56 (12%) 9 (21%) 5 (6%) 1 (20%)
Sites of infection
Feces 281 28 54 4
Urine 88 8 16 —
Nose/pharynx/throat 76 5 10 —
Mouth and sputum 10 1 — —
Conjunctives/eye 7 3 1 —
Blood 3 — — —
Sites of disease
Total no. of patients 42 7 — 1
Single organ involved 32 (76%) 4 (58%) — —
Multiple organs involved 10 (24%) 3 (42%) — 1 (20%)
Respiratory† tract/lung 31 4 5 1
Urinary‡ tract/kidney 20 2 — 1
Rectum 7 1 — —
Duodenum 7 — — —
Liver 6 2 — —
Stomach 5 1 — —
Esophagus 5 — — —
Spleen 4 1 — 1
Colon 3 3 — —
Brain 2 — — —
Lip 1 — — —
Skin 1 — — —
Methods of isolation
Conventional culture† 176 18 33 1
Stool culture† 81 10 7 —
EIA‡ 235 26 50 4
DFA 4 — 1 —
Shell vial culture 35 6 6 —
Biopsy/autopsy 42 7 — 1
*Patients were transplanted at Fred Hutchinson Cancer Research Center from 1978 through 1998
†Other than stool
‡On stool samples.
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tion, a second transplantation, and occurrence of
grade II-IV acute GVHD were statistically signiﬁ-
cantly associated with the probability of contracting
ADV infections (Table 4). T cell depletion was a risk
factor only after second transplantation (P  .005 by
Fisher’s exact test).
Younger patients and patients receiving HSCT
from a HLA mismatched sibling or an unrelated do-
nor were at higher risk of developing ADV disease
(OR0.8, 95% conﬁdence interval [CI] 0.7 to 1.0 [per
decade], P.06; OR2.3, 95% CI 1.2 to 4.6, P.02;
OR1.2, 95% CI .5 to 2.7, P.67; respectively).
Incidence of Adenovirus after Autologous Stem
Cell Transplantation
The overall incidence of ADV infections through-
out the study period and by any method of detection
after the ﬁrst or second autologous transplantation
was 6.3% (78/1219) and 6.5% (5/77), respectively.
CD34 cell-selected transplantations accounted for
only 9% (115/1219) of ﬁrst autologous transplanta-
tions and only 3% (4/115) of ADV infections were
reported. Characteristics of autologous patients devel-
oping ADV infections are reported in Table 5. Me-
dian time of detection was 24 days post ﬁrst transplan-
tation and 15 days post second transplantation. Patient
distributions by age and posttransplantation day of
detection are reported in Table 5. After the ﬁrst and
second transplantation, ADV were isolated from a
single site in 94% (73/78) and 80% (4/5) of cases,
respectively, and from multiple sites in 6% (5/78) and
Table 3. Univariate Models for Risk of Adenovirus Infections among
Allogeneic and Autologous Patients Transplanted at FHCRC from
August 1988 through August 1994
Hazard
Ratio 95% CI P Value
Allogeneic
Age at transplant* 0.84 0.77–0.93 <.0005
Disease risk
Low 1 — —
Intermediate 1.44 0.98–2.12 .07
High 1.37 0.92–2.05 .12
Patient/donor CMV serology
/ 1 — —
/ 1.09 0.77 to 1.53 .64
/ 0.72 0.48 to 1.08 .12
/ 0.74 0.45 to 1.21 .23
Patient/donor gender
M/M 1 — —
M/F 0.99 0.69–1.42 .97
F/M 0.65 0.43–0.98 .04
F/F 0.85 0.57–1.27 .43
Type of donor
Matched sibling 1 — —
Related HLA mismatched 1.75 1.22–2.50 .002
Unrelated 1.02 0.73–1.43 .90
First transplant 1 — —
Second transplant 2.03 1.21–3.39 .007
Year of transplant† 1.13 1.04–1.23 .006
Preparative regimen
TBI >12 cGy 10.74 — —
TBI <12 cGy 0.97 0.49–1.10 .14
BuCy 0.73 0.66–1.42 .88
BuCy TBI 1.27 0.39–1.34 .30
Other 0.79–2.06 .32
GVHD‡
Grade 0–1 1 — —
Grade II–IV 1.5 1.08–2.08 .02
Liver GVHD‡
Grade 0–1 1 — —
Grade II–IV 1.75 1.29–2.36 .0003
Gut GVHD‡
Grade 0–I 1 — —
Grade II–IV 2.06 1.49–2.85 <.0001
Skin GVHD‡
Grade 0–1 1 — —
Grade II–IV 1.7 1.22–2.36 .002
Bilirubin level§ 1.03 1.01–1.06 .01
Creatinine level§ 0.71 0.49–1.04 .08
Autologous
Age at transplant* 0.98 0.78–1.23 .84
Patient CMV serology
Negative 1 — —
Positive 0.75 0.38–1.51 .42
Patient gender
Female 1 — —
Male 1.21 0.61–2.42 .58
Year of transplant† 1.19 0.94–1.49 .15
Preparative regimen
TBI >12 cGy 1 — —
TBI <12 cGy 1.75 0.21–14.36 .60
BuCy 1.54 0.18–13.31 .69
BuCy TBI 1.66 0.18–14.95 .65
Other 3.09 0.39–24.63 .29
Bilirubin‡ 1.04 0.98–1.11 .21
Creatinine‡ 0.83 0.46–1.52 .55
*Treated as continuous variable; odds ratio presented per de-
cade.
†Treated as continuous variable; odds ratio presented per year.
‡GVHD any time, including after adenovirus.
§Treated as continuous variable; calculated as the average value
among all measurements to the last day of observation.
Table 4. Risk Factors Associated with Development of Adenovirus
Infections by Multivariable Regression*
Hazard
Ratio 95% CI P Value
Allogeneic
Age at transplant† 0.85 0.76–0.94 .001
Year at transplant‡ 1.27 1.14–1.42 <.0001
Transplant
First 1 — —
Second 2.34 1.26–4.36 .007
GVHD§
Grade 0–I 1 — —
Grade II–IV 1.49 1.05–2.11 .03
Ganciclovir use#
CMV receiving ganciclovir 1 — —
CMV 1.82 1.2–2.11 .005
CMV not receiving ganciclovir 3.39 2.08–5.52 <.0001
*Patients were transplanted at Fred Hutchinson Cancer Re-
search Center from 8/1988 through 8/1994.
†Treated as continuous variable; odds ratio presented per de-
cade.
‡Treated as continuous variable; odds ratio presented per year.
§GVHD any time, including after adenovirus.
#Patients who started ganciclovir prophylaxis after development
of adenovirus infection were counted as not having received ganci-
clovir.
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20% (1/5), respectively. Sites of isolation are reported
in Table 2. After the ﬁrst transplantation, ADV were
most frequently isolated from feces at a median of day
69 posttransplantation; the second and third most
frequent sites of isolation were urine and nose/phar-
ynx/throat at a median of day 21 and 13 posttrans-
plantation, respectively. After the second HSCT, the
most frequent site of isolation was feces.
Adenovirus Disease after Autologous Stem Cell
Transplantation
Among the 78 patients who developed ADV after
a ﬁrst transplantation, only 14% (11/78) had a tissue
biopsy during the posttransplantation period or had
an autopsy. No invasive ADV infection was observed
in this small cohort of patients. Five additional pa-
tients (6%; 5/78) had isolation of ADV from bron-
choalveolar lavage meeting the deﬁnition criteria of
ADV disease in the lungs. After the second transplan-
tation, only 1 patient (20%; 1/5), was found with
disseminated disease in the kidney, lung, and spleen at
autopsy.
Risk Factor Analysis
Univariate analyses are summarized in Table 3.
No factors were statistically signiﬁcantly correlated
with the probability of ADV infection among autolo-
gous patients.
Effect of Ganciclovir
Lack of ganciclovir prophylaxis or preemptive
therapy was a statistically signiﬁcant risk factor for the
development of ADV infection regardless of the CMV
serology at the time transplantation (OR1.82, 95%
CI 1.2 to 2.11, P.005; OR3.39, 95% CI 2.08 to
5.52, P .0001 in seronegative and seropositive pa-
tients, respectively) (Table 4). However, after adjust-
ing for type of donor and age, ganciclovir administra-
tion did not lead to a reduction of ADV disease
(OR1.2, P.72).
Incidence of Cytomegalovirus Infection and
Adenovirus Infection
A causal association between CMV infection/dis-
ease and the development of ADV infection/disease
was not observed. There was not any statistically sig-
niﬁcant difference of the incidence of CMV infection
between patients who never developed ADV infection
and those who developed ADV infection during the
posttransplantation course (21.3% and 25.5%, respec-
tively; P.10). Similar results were observed when
disease was considered. CMV disease occurred in
7.3% of non-ADV infected patients compared with
8.9% of ADV-infected patients (P.35). If occurrence
of CMV infection or disease is considered only before
the development of ADV infection or disease, respec-
tively, 14.9% of ADV-infected patients had preceding
CMV infection and 4.3% of patients with ADV dis-
ease had preceding CMV disease. Overall, though
there was a slight increase in CMV infection/disease
Table 5. Characteristics of Patients Developing Adenovirus Infections
after Autologous Hematopoietic Stem Cell Transplantation
Transplanted at FHCRC from 1978 through 1998
After First
Transplant (%)
After Second
Transplant (%)
No. of patients 78 (6.3) 5 (6.5)
Median age at
transplant (yrs) 40 (range, 1–63) 52 (range, 16–61)
Patient distribution
by age
0–20 20 (26) 2 (40)
21–30 7 (9) —
31–40 13 (17) —
41–50 19 (24) —
51–60 15 (19) 2 (40)
>61 4 (5) 1 (20)
Source of stem cells
Bone marrow 33 (42) 1 (20)
Peripheral blood 36 (46) 4 (80)
Bone marrow and
peripheral blood 5 (6) —
Bone marrow CD34 cells 4 (5) —
Diagnosis
Hematological
malignancies
ALL 5 (6) —
AML 16 (20) —
CML — —
HD 7 (9) 1 (20)
MDS — —
MM 7 (9) 1 (20)
NHL 16 (20) —
Breast cancer 14 (18) 1 (20)
Neuroblastoma 7 (9) —
Other solid tumor 6 (10) —
Other — 2 (40)
Conditioning regimen
TBI >12 cGy 3 (4) —
TBI <12 cGy 19 (24) —
BuCy 9 (12) —
BuCy TBI 6 (8) —
Other 41 (53) 5 (100)
Median day of detection
of ADV infection 24 15
Distribution by day of
detection of ADV
0–20 32 (4) 3 (60)
21–40 23 (29) 1 (20)
41–60 8 (10) 1 (20)
61–80 3 (4) —
81–100 8 (10) —
>101 4 (5) —
ALL indicates acute lymphoblastic leukemia; AML, acute my-
eloid leukemia; CML, chronic myeloid leukemia; HD, Hodgkin
disease; MDS, myelodysplastic syndrome; MM, multiple myeloma;
NHL, non-Hodgkin lymphoma; PNH, paroxysmal nocturnal he-
moglobinuria; GVHD, graft-versus-host disease; CSP, cyclospor-
ine; MTX, methotrexate; TBI, total body i rradiation; BU, busulfan;
Cy, cyclophosphamide.
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among patients with ADV compared with patients
without ADV, most cases of CMV occurred after the
development of ADV.
Incidence of Adenovirus Across Time
During the period August 1, 1988 through July 31,
1994, guidelines for ADV surveillance remained un-
modiﬁed. In this time window, the overall incidence of
ADV infections was 11.9% (240/2010) in allogeneic
HSCT and 7% (37/530) in autologous HSCT. Im-
portantly, the ADV incidence, based on viral detection
by EIA on stool samples and by culture techniques
from all other sites, was apparently increased across
time. However, in a regression model with year of
transplantation as the only explanatory variable, the
contribution to this signiﬁcant increase was caused
primarily by an increased detection of ADV by EIA on
stool samples as year of transplantation increased
(OR1.2, 95% CI 1.1 to 1.3; P .0001). When the
time window was extended through the end of the
study period, detection by EIA was still statistically
signiﬁcantly increased as year of transplantation in-
creased (OR1.1, 95% CI 1.0 to 1.1; P .01).
Survival
Median survival among allogeneic patients who
developed ADV infections after the ﬁrst or second
HSCT was 219 and 164 days, respectively; whereas
median survival among autologous patients who de-
veloped ADV infections after the ﬁrst or the second
HSCT was 303 and 387 days, respectively. Consider-
ing the occurrence of ADV as a time-dependant
covariate and adjusting for disease risk, age at trans-
plantation as a continuos variable, and type of trans-
plantation (matched related mismatched related v un-
related v autologous), patients who developed ADV
infections (detected by any method), had a statistically
signiﬁcant higher hazard of death compared with pa-
tients who did not develop ADV infections (hazard
ratio 1.5, 95% CI 1.3 to 1.7; P .0001).
Among patients with ADV, those who were ulti-
mately diagnosed with either overt or occult disease
had worse outcome compared to those who did not
develop disease (P .0001, Figure 2).
DISCUSSION
This study shows that ADV infection is associated
with increased mortality after controlling for known
factors that increase mortality in HSCT. The use of
ganciclovir for prevention of CMV was also associated
with a signiﬁcantly lower risk of developing ADV
infections. A second transplantation, occurrence of
acute GVHD, and younger age were statistically sig-
niﬁcant risk factors for developing the infection
among allogeneic recipients of non-T–cell depleted
HSCT. Similar to other studies performed in T-cell
depleted HSCT recipients, this study suggests that
there has been an increase of ADV infections in the
1990s.
In previous studies, the incidence of ADV in
HSCT has been reported to vary from 4.9% to
20.9%, with higher rates in pediatric patients and
T-cell depleted HSCT [9,12-17]. However, the real
incidence of ADV infections and ADV disease has
remained uncertain because of the retrospective na-
ture of most reports, where surveillance guidelines
and detection techniques varied over time. Recently, a
prospective study showed an incidence of 19% exclu-
sively in T-cell depleted transplantation patients [17].
Other reports on recipients of haploidentical trans-
plantations, which use even more intense T-cell de-
pletion and/or posttransplantation immunosuppres-
sion, showed an ADV disease incidence of 30% [42].
Though retrospective, one of the strengths of our
report is that guidelines for ADV surveillance and
methods of detection were rigorously applied
throughout the 7-year time window during which
statistical analyses were carried out. Overall, our inci-
dence of 8.5% in allograft recipients and 6.3% in
autograft recipients may be underestimated. In fact,
considering the period August 1988 through July 1994
(when weekly surveillance was performed), rates of
ADV infections were higher with an incidence of
11.9% and of 7% in allogeneic and autologous
HSCT, respectively. The overall increased incidence
in infection across time was demonstrated in this study
during the time period in which surveillance was uni-
form. Interestingly, the increased incidence was pri-
marily attributed to a signiﬁcantly increased detection
of ADV on stool samples by EIA. The reason for this
phenomenon remains unknown. Speciﬁcally, there
was no change in assay sensitivity during the study
period.
Figure 2. Probability of survival of patients diagnosed with disease
before the day of death, by tissue biopsy, compared with those with
ADV infection but not disease (P .0001).
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Among patients who had ADV infections, the
overall incidence of ADV disease was 9.3% and 6% in
allogeneic and autologous HSCT, respectively. Over
time, there was a trend toward less ADV disease (Fig-
ure 1). However, ADV disease may have been under-
diagnosed, because not all infected patients underwent
tissue biopsies or had autopsies. Moreover, one of the
reasons that might underestimate the rates of infec-
tion and disease is the difﬁculty in isolating certain
ADV strains with conventional methods.
In the general population, ADV infections occur
most frequently during childhood; commonly causing
upper respiratory tract syndromes, conjunctivitis, and
enteritis. Clusters of infections and seasonal outbreaks
of infections have been reported in small communities
such as hospitals, military quarters, and shipyards [1].
It is widely assumed that, after primary exposure,
ADV caused latent infections in lymphoid tissues in-
cluding tonsils and adenoids [43]. In our study, no
correlation between ADV infection and seasonal out-
break was noticed, suggesting endogenous viral reac-
tivation rather than airborne or droplet transmission
as other commonly diagnosed respiratory viruses in
the HSCT population [44-46]. Furthermore, the lack
of seasonal outbreaks suggests that the changes in
visitor policy during the study period did not contrib-
ute to viral transmission.
Acute GVHD and viral infections are the most
frequent causes of acute diarrhea after HSCT [47].
Moreover, isolation of enteric pathogens have also
been correlated with poor outcome [7]. Adenoviruses
have been reported to be a major enteric isolate in
transplantation patients with diarrhea [47-49]. Enteric
ADV primarily belong to serotypes 40 and 41, which
are not easily isolated through conventional cultures.
In our study, feces were the most common site of
ADV isolation, by both culture techniques and EIA,
and ADV disease was primarily diagnosed in the GI
tract; importantly, this was most frequently observed
in patients with negative cultures despite close surveil-
lance, probably underestimating real incidence and
clinical impact. Differential diagnosis between infec-
tious and noninfectious etiologies of diarrhea, such as
acute GVHD, can be difﬁcult. Because tissue biopsies
are frequently obtained to evaluate gut GVHD, pa-
thologists should be alert to the possibility that these
biopsies will also display invasive ADV disease. Use of
endoscopic biopsy specimen and polymerase chain
reaction (PCR)-based assays to detect ADV should be
considered in prospective studies to evaluate the real
incidence of GI disease and possibly correlate the
presence of ADV with a worse clinical course of
GVHD.
Several differences were observed between the au-
tologous and allogeneic HSCT populations. In the
former, the incidence was lower and did not differ
substantially between ﬁrst and second HSCT. More-
over, no risk factors were statistically signiﬁcantly as-
sociated with the development of ADV. The number
of patients (and the number of cases of ADV), how-
ever, limited the power to detect such associations
relative to the allogeneic population. In allogeneic
patients, as previously reported [12-15], factors statis-
tically signiﬁcantly associated with ADV were GVHD
and a second transplantation. Both these conditions
heavily reduce the host immune competence, which
facilitates viral reactivation and the acquisition of in-
fections. Chakrabarti et al.[17] recently reported a
signiﬁcantly higher incidence of ADV with increased
intensity of immunosuppression which included T-
cell depletion. In our study, the difference of the
incidence between autologous and allogeneic HSCT,
and the risk factors associated with the latter, are
consistent with this ﬁnding. However, it is noteworthy
that the incidence of ADV infection after the ﬁrst
T-cell depleted transplantation was not higher in our
series of patients compared with that observed after
the ﬁrst T-cell repleted transplantation, suggesting
that differences in the T-cell depletion methods are
important and that the in vivo use of alemtuzumab
might be particularly immunosuppressive [17,34-37].
No proven efﬁcacious antiviral therapy is cur-
rently known for ADV infections. Mixed results have
been reported for a number of antiviral agents includ-
ing intravenous vidarabine and ribavirin [6,19,22-
26,29,31]. In our study, the use of ganciclovir, used as
preemptive or prophylactic strategy for CMV infec-
tions, moderately reduced the incidence of ADV in-
fections, indicating a possible role in the prophylaxis
of ADV infections as well. In vitro activity of ganci-
clovir against ADV has been reported [32]. Moreover,
anecdotal studies report successful treatment of ADV
infections with ganciclovir [21]. We did not observe a
correlation between incidence of CMV infection/dis-
ease and incidence of ADV infection/disease. The
incidence of CMV was similar between the group of
patients who developed ADV posttransplantation and
those who did not. Furthermore, in the group of
patients with either ADV infection or ADV disease,
onset of CMV infection/disease occurred most often
after the development of ADV, suggesting that CMV
does not promote ADV reactivation. Cidofovir re-
mains the antiviral agent with the strongest activity
against ADV in vitro [18,20,30]. Initial encouraging
results as ﬁrst-line and salvage treatments have been
reported, though toxicity remained high [18]. More
recently, a study on pediatric patients reported lower
toxicity by reducing the dosing regimen and increas-
ing the frequency of administration [50].
Adoptive immunotherapy with donor lymphocyte
infusion has been useful in a number of viral infec-
tions, including ADV [17,26,27]. Speciﬁc CD4 T
cells and CD8 T cells against structural and regula-
tory ADV proteins have been reported [51,52] None-
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theless, donor lymphocyte infusion is only potentially
useful to patients without GVHD.
Importantly, the prevention of viral dissemination
and tissue invasion by early diagnosis appears crucial
for successful treatment. Chakrabarti et al. [17]
showed that the detection of ADV DNA by blood
PCR in 2 patients predicted fatal outcome. Prospec-
tive studies to evaluate the predictive value of early
detection of viral DNA, by readily available PCR
techniques to the subgenus level [53-56] or quantita-
tive PCR [42] in body ﬂuids and/or tissue specimen,
may address the issue of the most appropriate timing
of antiviral therapy. Moreover, PCR-guided preemp-
tive therapy, as for CMV [57,58] or prophylaxis rather
than treatment of established disease, could lead to an
improvement of overall survival in patients with ADV
infections.
In summary, this study shows that ADV infection
is an increasing problem and is associated with poor
outcome in non-T–cell depleted transplantation re-
cipients. The association with mortality may be be-
cause of both lytic infection and indirect immunosup-
pressive effects leading to increased bacterial and
fungal infections, similar to those described with
CMV and other respiratory viruses [45,59,60]. More
research is needed to determine the true impact of
ADV on transplantation outcome. The results with
ganciclovir, which has only moderate activity against
ADV, could provide the basis for prevention strategies
with more potent anti-ADV drugs such as cidofovir
[59]. Large prospective studies to optimize diagnosis
and the use of currently available antiviral agents are
needed because the indications for HSCT have
greatly increased after the introduction of nonmyelo-
ablative conditionings and the larger application of
T-cell depleted transplantation procedures.
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